论文部分内容阅读
急性放射病时使用造血生长因子治疗,不仅有一定的理论依据,而且得到各种动物整体病理模型试验,大剂量化疗及骨髓移植等与急性放射病有类似病理过程的一些疾病临床试验的间接证实,以及两起核事故病人临床治疗资料的直接证实.在核事故的复杂情况下,使用造血生长因子有着显著的优越性.造血生长因子的使用为急性放射病的治疗提供了一种新的手段,标志着急性放射病治疗研究新时代的开始.
The use of hematopoietic growth factor in the treatment of acute radiation sickness not only has certain theoretical basis but also indirectly confirms the clinical trials of some diseases with similar pathological course of acute radiation sickness, such as various animal pathological model tests, high-dose chemotherapy and bone marrow transplantation, and Direct verification of clinical data on two patients with nuclear accidents In the complex case of a nuclear accident the use of hematopoietic growth factors has significant advantages.The use of hematopoietic growth factors provides a new tool for the treatment of acute radiation sickness, The beginning of a new era of acute radiation therapy research.